drugset / Trial / NCT04056481

Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

NCT04056481

Expanded access Approved for marketing Alnylam Pharmaceuticals

Summary

The purpose of this study is to provide expanded access of givosiran to patients with Acute Hepatic Porphyria (AHP).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Givosiran Small interfering RNA (siRNA) Subcutaneous

Indications